S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Cara Therapeutics Stock Forecast, Price & News

+0.01 (+0.06 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $18.09
50-Day Range
MA: $19.33
52-Week Range
Now: $18.09
Volume648,484 shs
Average Volume549,615 shs
Market Capitalization$902.27 million
P/E RatioN/A
Dividend YieldN/A
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Cara Therapeutics logo


Preview: Cara Therapeutics's Earnings
February 24, 2021 |  finance.yahoo.com
Notable Wednesday Option Activity: GM, CARA, FLR
February 10, 2021 |  nasdaq.com
Is CARA A Good Stock To Buy Now?
December 18, 2020 |  finance.yahoo.com
CARA Dec 2020 12.500 call
December 3, 2020 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CARA
Year FoundedN/A



Sales & Book Value

Annual Sales$19.89 million
Book Value$4.66 per share


Net Income$-106,370,000.00
Net Margins-360.35%


Market Cap$902.27 million
Next Earnings Date5/10/2021 (Estimated)


Overall MarketRank

1.78 out of 5 stars

Medical Sector

175th out of 1,972 stocks

Pharmaceutical Preparations Industry

78th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.01 (+0.06 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CARA News and Ratings via Email

Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

Is Cara Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cara Therapeutics stock.
View analyst ratings for Cara Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Cara Therapeutics?

Wall Street analysts have given Cara Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cara Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Cara Therapeutics

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) announced its quarterly earnings results on Thursday, February, 25th. The biopharmaceutical company reported $1.59 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.53) by $2.12. Cara Therapeutics had a negative trailing twelve-month return on equity of 64.36% and a negative net margin of 360.35%.
View Cara Therapeutics' earnings history

How has Cara Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Cara Therapeutics' stock was trading at $13.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CARA stock has increased by 34.7% and is now trading at $18.09.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CARA?

4 equities research analysts have issued 12-month price targets for Cara Therapeutics' stock. Their forecasts range from $30.00 to $40.00. On average, they expect Cara Therapeutics' stock price to reach $34.50 in the next twelve months. This suggests a possible upside of 90.7% from the stock's current price.
View analysts' price targets for Cara Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the following people:
  • Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 57, Pay $881.83k)
  • Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 55, Pay $597.83k)
  • Mr. Scott M. Terrillion, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 58, Pay $571.03k)
  • Dr. Michael E. Lewis, Co-Founder & Chief Scientific Advisor (Age 69)
  • Mr. Thomas Charles Reilly, Chief Financial Officer
  • Mr. Richard Makara, VP, Head of Accounting, Controller & Principal Accounting Officer (Age 50)
  • Mr. Eric Vandal, Sr. VP of Commercial
  • Dr. Joana Goncalves, Chief Medical Officer (Age 47)

Who are some of Cara Therapeutics' key competitors?

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), 22nd Century Group (XXII), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.29%), Price T Rowe Associates Inc. MD (4.87%), Northern Trust Corp (1.06%), ETF Managers Group LLC (0.87%), Frontier Capital Management Co. LLC (0.76%) and Nuveen Asset Management LLC (0.75%). Company insiders that own Cara Therapeutics stock include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, Martin Vogelbaum and Scott Terrillion.
View institutional ownership trends for Cara Therapeutics

Which institutional investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, ETF Managers Group LLC, Nuveen Asset Management LLC, Assenagon Asset Management S.A., BlackRock Inc., Pinnacle Associates Ltd., Renaissance Technologies LLC, and Alliancebernstein L.P.. Company insiders that have sold Cara Therapeutics company stock in the last year include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, and Scott Terrillion.
View insider buying and selling activity for Cara Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Cara Therapeutics stock?

CARA stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Penserra Capital Management LLC, Alpine Woods Capital Investors LLC, Russell Investments Group Ltd., Virginia Retirement Systems ET AL, DNB Asset Management AS, Wells Fargo & Company MN, and Woodstock Corp.
View insider buying and selling activity for Cara Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $18.09.

How much money does Cara Therapeutics make?

Cara Therapeutics has a market capitalization of $902.27 million and generates $19.89 million in revenue each year. The biopharmaceutical company earns $-106,370,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis.

How many employees does Cara Therapeutics have?

Cara Therapeutics employs 80 workers across the globe.

What is Cara Therapeutics' official website?

The official website for Cara Therapeutics is www.caratherapeutics.com.

Where are Cara Therapeutics' headquarters?

Cara Therapeutics is headquartered at 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.